Trial Profile

Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MK 2206 (Primary)
Indications Adenocarcinoma; Breast cancer
Focus Therapeutic Use

Most Recent Events

01 Aug 2021 Results (n=7) of a proof of principle study assessing whether Diffuse optical tomography breast imaging system-derived measurements are modifiable with targeted therapies ; patients were enrolled from three clinical studies: NCT02598557, NCT01319539 and NCT02712723 published in the Breast Cancer Research and Treatment
05 Jun 2018 Results assessing the impact of Akt inhibition on the tumor microenvironment, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
09 Dec 2017 Results assessing tumor immune environment in Breast cancer patients presented at the 40th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com